Mobile

Managing neovascular age-related macular degeneration over 2 years using of different schedules of 2 mg aflibercept injected in the eye (ARIES)

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-003132-39

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess whether 2 mg IVT aflibercept administered in an early-start T&E regimen (initiated after the first 8-weekly treatment interval) is non-inferior to 2 mg IVT aflibercept administered in a late-start T&E regimen (initiated at the end of Year 1, per label) in subjects with nAMD

Critère d'inclusion

  • Neovascular Age-Related Macular Degeneration
  • (nAMD)

Liens